326 related articles for article (PubMed ID: 38111570)
1. Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.
Lan HR; Chen M; Yao SY; Chen JX; Jin KT
Front Immunol; 2023; 14():1266450. PubMed ID: 38111570
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
Huang S; van Duijnhoven SMJ; Sijts AJAM; van Elsas A
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3111-3122. PubMed ID: 32989604
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
4. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade.
Xu L; Li B; Pi C; Zhu Z; Tao F; Xie K; Feng Y; Xu X; Yin Y; Gu H; Fang J
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460336
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies for the treatment of breast cancer.
Dillon PM; Tushir-Singh J; Lum LG
Expert Opin Biol Ther; 2022 Aug; 22(8):1017-1027. PubMed ID: 33896311
[TBL] [Abstract][Full Text] [Related]
8. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy.
Geng Q; Jiao P
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257366
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.
Farhangnia P; Ghomi SM; Akbarpour M; Delbandi AA
Front Immunol; 2023; 14():1155778. PubMed ID: 37441075
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.
Cheng L; Chen L; Shi Y; Gu W; Ding W; Zheng X; Liu Y; Jiang J; Zheng Z
Mol Cancer; 2024 Apr; 23(1):77. PubMed ID: 38627681
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic bispecific antibodies against intracellular tumor antigens.
Xu G; Luo Y; Wang H; Wang Y; Liu B; Wei J
Cancer Lett; 2022 Jul; 538():215699. PubMed ID: 35487312
[TBL] [Abstract][Full Text] [Related]
13. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
14. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
15. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.
You G; Won J; Lee Y; Moon D; Park Y; Lee SH; Lee SW
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358141
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
Pandey MS; Wang C; Umlauf S; Lin S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
[TBL] [Abstract][Full Text] [Related]
17. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.
Guo X; Wu Y; Xue Y; Xie N; Shen G
Front Immunol; 2023; 14():1291836. PubMed ID: 38106416
[TBL] [Abstract][Full Text] [Related]
18. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
[TBL] [Abstract][Full Text] [Related]
19. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies for treatment of cancer in experimental animal models and man.
de Leij L ; Molema G; Helfrich W; Kroesen BJ
Adv Drug Deliv Rev; 1998 Apr; 31(1-2):105-129. PubMed ID: 10837620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]